This site is intended for US Health Care Professionals only.
PROVENGE is immunotherapy for asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (mCRPC)
At the time of metastatic diagnosis
of CRPC patients may be eligible for PROVENGE2
Treat Early - make sure your patients take advantage of the PROVENGE window
Dendreon ON Call – Supporting Your Practice and Your Patients
Personalized Support For Your PROVENGE Patients Is Just A Call Away...We Have You Covered
Sustained Immune Response And Short Duration Of Treatment*
You are now leaving PROVENGEhcp.com. We are not responsible for content on the third-party Web site to which you will be going. Please review our Web site Terms of Use and Privacy Policy for further information.
Continue 自由动态网翻墙手机版
This content is intended for US health care professionals only and by clicking YES I am confirming that I am a health care provider.
Yes NO, I am not a HCP. Go to PROVENGE.com
Your e-mail has been sent. To learn more about PROVENGE, please see the Full Prescribing Information.
If you’d like to send this site to a colleague, please complete the form below and click "Submit." The recipient will receive an e-mail with a direct URL link to this information, along with a notification that you requested to send it. Your personal information has not been stored by Dendreon, and your e-mail address will not be shared with any third parties. For more information, please see our 自由之门翻墙最新手机版.
To learn more about PROVENGE, please see the Full Prescribing Information.
Dendreon uses cookies to analyze traffic, enhance your experience, and provide you with tailored content. By continuing to use this site, you agree with our use of cookies and our Privacy Policy. For more information or to opt-out of sale, visit our Privacy Policy.